Medicare Formulary Coverage and Restrictions for Opioid Potentiators from 2013 to 2017

Aishwarya Vijay; Joseph S. Ross; Nilay D. Shah; Molly M. Jeffery; Sanket S. Dhruva

doi:10.1007/s11606-018-4752-8

Medicare Formulary Coverage and Restrictions for Opioid Potentiators from 2013 to 2017

Aishwarya Vijay, Joseph S. Ross, Nilay D. Shah, Molly M. Jeffery, Sanket S. Dhruva

Quantitative Health Sciences

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	518-520
Number of pages	3
Journal	Journal of general internal medicine
Volume	34
Issue number	4
DOIs	https://doi.org/10.1007/s11606-018-4752-8
State	Published - Apr 15 2019

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.1007/s11606-018-4752-8

Cite this

@article{5d849788915442988be280d056350f93,

title = "Medicare Formulary Coverage and Restrictions for Opioid Potentiators from 2013 to 2017",

author = "Aishwarya Vijay and Ross, {Joseph S.} and Shah, {Nilay D.} and Jeffery, {Molly M.} and Dhruva, {Sanket S.}",

note = "Funding Information: Conflict of Interest: Over the past 36 months, Dr. Ross received support through Yale University from the Food and Drug Administration as part of the Centers for Excellence in Regulatory Science and Innovation (CERSI) program, from Johnson and Johnson to develop methods of clinical trial data sharing, from Medtronic, Inc. and the Food and Drug Administration (FDA) to develop methods for postmarket surveillance of medical devices, from the Blue Cross Blue Shield Association to better understand medical technology evaluation, from the Centers for Medicare and Medicaid Services (CMS) to develop and maintain performance measures that are used for public reporting, from the Agency for Healthcare Research and Quality (AHRQ) to examine community predictors of healthcare quality, and from the Laura and John Arnold Foundation, which established the Collaboration for Research Integrity and Transparency (CRIT) at Yale University. Dr. Shah received support from the Food and Drug Administration as part of the Centers for Excellence in Regulatory Science and Innovation (CERSI) program, through the Mayo Clinic from the Centers for Medicare and Medicaid Services (CMS), Agency for Healthcare Research and Quality (AHRQ), National Science Foundation, and Patient-centered Outcomes Research Institute (PCORI). All remaining authors declare that they do not have a conflict of interest. Funding Information: Acknowledgements: During the conduct of this work, Dr. Dhruva was supported by the National Clinician Scholars Program and the Department of Veterans Affairs. Ms. Vijay received a student research grant provided by the Yale School of Medicine Office of Student Research.",

year = "2019",

month = apr,

day = "15",

doi = "10.1007/s11606-018-4752-8",

language = "English (US)",

volume = "34",

pages = "518--520",

journal = "Journal of General Internal Medicine",

issn = "0884-8734",

publisher = "Springer New York",

number = "4",

}

TY - JOUR

T1 - Medicare Formulary Coverage and Restrictions for Opioid Potentiators from 2013 to 2017

AU - Vijay, Aishwarya

AU - Ross, Joseph S.

AU - Shah, Nilay D.

AU - Jeffery, Molly M.

AU - Dhruva, Sanket S.

N1 - Funding Information: Conflict of Interest: Over the past 36 months, Dr. Ross received support through Yale University from the Food and Drug Administration as part of the Centers for Excellence in Regulatory Science and Innovation (CERSI) program, from Johnson and Johnson to develop methods of clinical trial data sharing, from Medtronic, Inc. and the Food and Drug Administration (FDA) to develop methods for postmarket surveillance of medical devices, from the Blue Cross Blue Shield Association to better understand medical technology evaluation, from the Centers for Medicare and Medicaid Services (CMS) to develop and maintain performance measures that are used for public reporting, from the Agency for Healthcare Research and Quality (AHRQ) to examine community predictors of healthcare quality, and from the Laura and John Arnold Foundation, which established the Collaboration for Research Integrity and Transparency (CRIT) at Yale University. Dr. Shah received support from the Food and Drug Administration as part of the Centers for Excellence in Regulatory Science and Innovation (CERSI) program, through the Mayo Clinic from the Centers for Medicare and Medicaid Services (CMS), Agency for Healthcare Research and Quality (AHRQ), National Science Foundation, and Patient-centered Outcomes Research Institute (PCORI). All remaining authors declare that they do not have a conflict of interest. Funding Information: Acknowledgements: During the conduct of this work, Dr. Dhruva was supported by the National Clinician Scholars Program and the Department of Veterans Affairs. Ms. Vijay received a student research grant provided by the Yale School of Medicine Office of Student Research.

PY - 2019/4/15

Y1 - 2019/4/15

UR - http://www.scopus.com/inward/record.url?scp=85059860665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059860665&partnerID=8YFLogxK

U2 - 10.1007/s11606-018-4752-8

DO - 10.1007/s11606-018-4752-8

M3 - Article

C2 - 30623386

AN - SCOPUS:85059860665

SN - 0884-8734

VL - 34

SP - 518

EP - 520

JO - Journal of General Internal Medicine

JF - Journal of General Internal Medicine

IS - 4

ER -

Medicare Formulary Coverage and Restrictions for Opioid Potentiators from 2013 to 2017

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this